Document Detail


Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options.
MedLine Citation:
PMID:  20956119     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition in which organised thrombi obstruct the pulmonary vessels, causing increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right heart failure. The treatment of choice is pulmonary endarterectomy, which restores pulmonary haemodynamics with acceptable periprocedural mortality rates in the majority of suitable patients. However, CTEPH may be inoperable owing to surgically inaccessible thrombi or comorbid diseases that confer an unacceptably high risk. Pharmacotherapies, although not yet approved, may be useful in this situation or for treating residual or recurrent PH following surgery. Vasodilator drugs for PH are attracting growing interest as potential treatments for CTEPH because this disease has recently been labelled as a "dual" pulmonary vascular disorder: major vessel obstruction and remodelling is combined with a small vessel arteriopathy that is histologically indistinguishable from the classical pulmonary arteriopathy observed in pulmonary arterial hypertension. Of three completed randomised controlled trials in patients with CTEPH, only one was powered to detect a treatment effect. The BENEFIT trial employed the dual endothelin-receptor antagonist bosentan. Although haemodynamics improved significantly, the second component of the primary end-point, exercise capacity, was not met. More evidence is required to resolve whether vasodilator treatments are beneficial for inoperable chronic thromboembolic pulmonary hypertension.
Authors:
I M Lang
Related Documents :
3053179 - Experimental prevention of hypoxic pulmonary hypertension in animals by drugs.
8820089 - Comparison of the hemodynamics and survival of adults with severe primary pulmonary hyp...
8287439 - Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hyper...
20879069 - Pulmonary hypertension associated with use of phentermine.
20479949 - The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypert...
8903609 - Small-artery changes in hypertension.
3053179 - Experimental prevention of hypoxic pulmonary hypertension in animals by drugs.
22778569 - Strategies for successful percutaneous revascularization of chronic total occlusion of ...
16703209 - The application of split-thickness skin graft as an autogenous arterial conduit in a go...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European respiratory review : an official journal of the European Respiratory Society     Volume:  18     ISSN:  1600-0617     ISO Abbreviation:  Eur Respir Rev     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2011-02-07     Revised Date:  2012-01-10    
Medline Journal Info:
Nlm Unique ID:  9111391     Medline TA:  Eur Respir Rev     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  24-8     Citation Subset:  IM    
Affiliation:
Dept of Cardiology, Medical University of Vienna, Austria. irene.lang@meduniwien.ac.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chronic Disease
Humans
Hypertension, Pulmonary / drug therapy*,  etiology
Pulmonary Embolism / complications,  drug therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs.
Next Document:  Inhaled iloprost for the treatment of pulmonary hypertension.